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ABSTRACT
An increased incidence of invasive fungal infections, especially those caused by ﬁlamentous fungi, has
been observed among high-risk patients such as allogeneic stem-cell transplant recipients and those
with acute leukaemia receiving high-dose chemotherapy. Despite signiﬁcant progress in the prevention
and treatment of fungal infections, invasive aspergillosis continues to be a major cause of morbidity and
mortality. Development of more efﬁcient therapeutic and prophylactic strategies with currently
available and new antifungal agents, as well as of sensitive and speciﬁc methods for early diagnosis, is
needed. In addition, an increasing incidence of invasive infections caused by Zygomycetes is of concern.
Several reports of breakthrough zygomycosis in patients receiving voriconazole have raised the
possibility of a relationship between voriconazole use and increased risk of Zygomycetes infection,
although evidence of a deﬁnite causal relationship remains controversial. The potential impact that all
therapeutic and prophylactic changes can have on the emergence of ‘new’ pathogens should be kept in
mind.
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INTRODUCTION
An increased incidence of invasive fungal infec-
tions has been particularly evident in patients
with cancer over the past decades, particularly in
haematopoietic stem-cell transplant recipients
and patients with haematological malignancies
[1–7]. In addition, a marked shift in the spectrum
of causative organisms is increasingly being
reported, with ﬁlamentous fungi gaining predom-
inance. Indeed, until the 1990s, candidiasis was
the most common invasive fungal infection in
neutropenic patients, whereas during the past
decade, invasive mould infections have become
the most frequent fungal infections among
patients at high risk, especially those receiving
allogeneic stem-cell transplants or very intensive
chemotherapy for acute leukaemias [8,9].
Although several explanations can be given for
this radical change in the prevalence of fungi in
invasive mycoses, the routine use of ﬂuconazole
prophylaxis, the increased intensity of chemo-
therapy, and the growing practice of allogeneic
stem-cell transplantation from unrelated donors
over the past decade, among other factors, clearly
seem to be involved. In addition, although
Aspergillus spp. account for the majority of inva-
sive ﬁlamentous fungal infections, other emerging
opportunistic fungalpathogenshavebeen reported
over the last 20 years [10–12]. The present review
summarises some of the new developments in
the epidemiology of invasive aspergillosis and
zygomycosis.
EPIDEMIOLOGY OF ASPERGILLOSIS
Currently, invasive aspergillosis is probably the
major clinical problem among invasive fungal
infections. Although underlying conditions pre-
disposing to this infectious complication include
malignancy, haematopoietic stem-cell or solid-
organ transplantation, and congenital or acquired
immunodeﬁciencies, the present review focuses
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on epidemiological considerations in patients
with haematological malignancies and in haema-
topoietic stem-cell transplant recipients, in whom
invasive aspergillosis is the most prevalent mould
infection and a major cause of morbidity and
mortality.
During the last decade, several epidemiological
factors have contributed to the increasing concern
about invasive aspergillosis. Several reports have
shown a rising prevalence of invasive aspergil-
losis upon autopsy over recent decades world-
wide [13–17], surpassing invasive candidiasis as
the most frequent fungal infection found at
autopsy at some tertiary-care centres [1,15–17].
Moreover, this epidemiological increase in the
incidence of aspergillosis and the decrease in
candidiasis have been widely reported, not only
at autopsy, but also upon evaluation of microbio-
logical isolates from patients with a diagnosis of
possible, probable or proven invasive fungal
infection. The routine prophylactic use of ﬂucon-
azole over the past decade is certainly implicated
in the dramatic decrease in the incidence of
invasive candidiasis, and has also contributed
substantially to the emergence of invasive asper-
gillosis as the most common invasive fungal
infection [16].
We have observed similar epidemiological
changes in our Leukaemia and Stem Cell Trans-
plant Unit at the University Hospital La Fe. We
identiﬁed 131 cases of invasive aspergillosis
between January 1988 and December 2003
(Fig. 1). During the ﬁrst half of this period, the
incidence of invasive aspergillosis was relatively
stable at 25 cases per 1000 admissions, while in
the last 8 years it has continuously increased.
Acute leukaemia and allogeneic haematopoetic
stem-cell transplantation are also the most fre-
quent underlying conditions in our Haematology
Unit. Although several factors may have been
involved in the increase in the incidence, it
should be noted that the number of allogeneic
stem-cell transplants, especially those using bone
marrow and cord blood from unrelated donors as
the source of stem cells, has signiﬁcantly in-
creased at our institution during recent years.
Among 407 stem-cell transplants performed from
1999 to 2003, the overall incidence of invasive
aspergillosis was 6.8%, but it has dramatically
increased from less than 2 per 100 transplants
during the ﬁrst 3 years to 17.5 per 100 transplants
during the last year (Fig. 2). We can speculate
about a possible nosocomial cluster associated
with hospital construction works, defects in air-
handling equipment, and other environmental
factors; however, the number of cases may
sometimes appear to be a cluster when in fact it
is not [17]. Although it is still too early to evaluate
the individual impact of several measures that
were implemented almost simultaneously to
decrease the incidence of aspergillosis in our
unit, it seems that the introduction of systematic
itraconazole prophylaxis for patients with acute
leukaemia and for allogeneic stem-cell transplant
recipients has certainly contributed to the attain-
ment of a signiﬁcant reduction (unpublished
data).
Although the incidence of invasive aspergil-
losis in other haematological malignancies, e.g.,
multiple myeloma, non-Hodgkin’s lymphoma,
and other lymphoproliferative diseases, is much
Fig. 1. Trends in fungal infections (probable and proven
cases) in the Haematology Service at University Hospital
La Fe over a 15-year period. Fluco-S: Fluconazole-suscep-
tible; Fluco-R: Fluconazole-resistant.
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Fig. 2. Incidence of aspergillosis in stem-cell transplant
(SCT) recipients in the Haematology Service at University
Hospital La Fe (1999–2003).
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less than that reported in patients with acute
leukaemia, an increase in opportunistic infections
has been also suggested, including invasive fun-
gal infections, in parallel with the use of more
aggressive therapeutic approaches during recent
years. The use of more intensive chemotherapy
and highly immunosuppressive drugs, e.g.,
ﬂudarabine or alemtuzumab, has certainly con-
tributed to an improved outcome of lymphopro-
liferative diseases, but it has also increased the
risk of opportunistic infections, including inva-
sive aspergillosis.
It is generally accepted that the epidemiology
of invasive aspergillosis is complex and that
many epidemiological issues still remain contro-
versial. Regarding the nosocomial or community-
acquired origin of this particular fungal infection,
it is assumed that most cases of invasive asper-
gillosis in immunocompromised hosts are of
nosocomial origin, the air being the most import-
ant source of Aspergillus. However, the proportion
of patients who become infected from alternative
sources has not been well-determined. In fact, a
considerable number of cases of invasive asper-
gillosis in allogeneic stem-cell transplant recipi-
ents occur in the outpatient setting. In these
patients, who are severely immunosuppressed for
prolonged periods after engraftment, with alter-
nating periods of hospitalisation and home
residence, but always under potent immunosup-
pressive therapies, it is very difﬁcult to establish
the actual origin of the infection in individual
cases.
To add to the complexity of and the concern
about the potential sources of Aspergillus contam-
ination, a recent study found that cotton fabric
harbours and disperses Aspergillus spores more
readily than other types of fabric [18]. This ﬁnding
leads us to speculate that cotton clothing worn by
hospital personnel and visitors may serve as a
source of Aspergillus exposure for susceptible
patients [1]. Finally, as Kontoyiannis and Bodey
reported recently [1], the available epidemiolog-
ical evidence implicating the hospital water res-
ervoir systems in the acquisition of nosocomial
invasive aspergillosis is weak [19] and still
remains controversial [20].
Despite the signiﬁcant progress in the treat-
ment of invasive aspergillosis, the mortality rate is
still high and the ﬁnancial burden of invasive
aspergillosis-associated hospitalisation is enor-
mous.
EPIDEMIOLOGY OF ZYGOMYCOSIS
Within the class Zygomycetes, the order Muco-
rales includes the genera Rhizopus, Mucor and
Rhizomucor, which are the pathogens most fre-
quently implicated in human zygomycosis. Sev-
eral recent reports have called attention to the
increase in the incidence of invasive infections
caused by the Zygomycetes, particularly in recip-
ients of haematopoietic stem-cell transplants and
patients with haematological malignancies.
However, contrasting with infection by other
ﬁlamentous fungi that mainly target immuno-
compromised hosts, zygomycosis is frequently
observed in a broader population of patients,
including those with poorly controlled diabetes
mellitus, and those receiving deferoxamine ther-
apy for iron overload, among others [2]. As with
aspergillosis, the present review focuses on epi-
demiological considerations in patients with
haematological malignancies and in haematopoi-
etic stem-cell transplant recipients.
The epidemiology and outcome of this emerg-
ing life-threatening fungal infection have been
outstandingly reviewed recently by Roden et al.
[2] This is the ﬁrst comprehensive review in the
English-language literature concerning zygomy-
cosis since the original case report in 1885. This
review analyses 929 eligible cases in whom the
zygomycosis had been conﬁrmed either histolog-
ically or by culture, and describes the underlying
condition, the anatomical location of infection, the
surgical and antifungal treatments, and the out-
come. Although the ﬁrst reported case of zyg-
omycosis was in 1885 [21], the ﬁrst eligible case
that met the predeﬁned criteria was reported in
1940.
One of the most striking observations during
the course of writing this review was that diabetes
was the most common underlying condition
(36%), and the next largest patient population
had no primary underlying disease (19%). Fur-
thermore, malignancy was an underlying condi-
tion in the third largest patient population (17%),
with haematological malignancy being the under-
lying condition in 95% of these cases. Regarding
the sites and patterns of infection, there were
signiﬁcant differences according to the host pop-
ulation. The patterns observed in patients with
malignancy and in stem-cell transplant recipients
are shown in Table 1. The lungs constituted more
than one-half of all sites of infection in patients
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with malignancy and in stem-cell transplant
recipients (60% and 52%, respectively), while
sinuses were the second most common site
involved in these patients.
Rhizopus and Mucor were the most commonly
recovered genera (50% and 18%, respectively). In
this study, zygomycosis was apparently more
prevalent among males. Finally, multivariate
regression analysis of risk-factors showed that
disseminated disease, renal failure and infection
with Cunninghamella species had an adverse
inﬂuence on mortality. Pulmonary, rhino-cereb-
ral, kidney and gastrointestinal infection were
associated with the highest risk of mortality.
Recently, attention has been called to the
possible association of voriconazole with an
increased risk of infection caused by Zygomycetes
[12]. This association is supported by several
reports of breakthrough zygomycosis in patients
receiving voriconazole [22–26]. Voriconazole has
broad-spectrum antifungal activity and is especi-
ally active against Aspergillus species and other
ﬁlamentous fungi, but it has no activity against
the Zygomycetes [27]. However, a deﬁnite causal
relationship between treatment with voriconazole
and the emergence of breakthrough infections
caused by Zygomycetes is far from established. In
fact, although the use of voriconazole may have
contributed to the occurrence of zygomycosis,
there are some data indicating that the incidence
of zygomycosis was increasing before the intro-
duction of voriconazole into clinical practice [12].
Data from two large transplant centres in the USA
show that an increase in the incidence of zyg-
omycosis was already apparent in the mid-1990s
[28,29], leading to speculation that the apparent
increase in the incidence of zygomycosis may be
an ampliﬁcation of this phenomenon [12]. How-
ever, a recent prospective surveillance study of 27
patients with zygomycosis (case-control observa-
tional study) carried out at the MD Anderson
Cancer Center found that voriconazole prophy-
laxis was a factor that favoured zygomycosis [30].
CONCLUSIONS
In the context of an increasing incidence of
invasive fungal infections in patients with haem-
atological malignancies and in haematopoietic
stem-cell transplant recipients, ﬁlamentous fungi
have increasingly been reported as the causative
organisms over the past decade. Despite signiﬁ-
cant progress in the prevention and treatment of
fungal infections, invasive aspergillosis is still a
major cause of morbidity and mortality in these
patients. More efﬁcient therapeutic and prophy-
lactic strategies, involving the currently available
antifungal agents and new antifungal agents, as
well as sensitive and speciﬁc methods for early
diagnosis, are needed. The potential impact that
therapeutic and prophylactic changes can have on
the emergence of ‘new’ pathogens should be kept
in mind. For example, the possible association of
the use of voriconazole and an increased risk of
infection caused by resistant organisms such as
Zygomycetes has been reported recently.
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